# EDGAR Filing Document

**Accession Number:** 0001892134
**File Stem:** 0001892134-25-000009
**Filing Date:** 2025-9
**Character Count:** 26139
**Document Hash:** 048fcc4913ca2891bd2e477dd5fa799c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001892134-25-000009.hdr.sgml**: 20250905

**ACCESSION NUMBER**: 0001892134-25-000009

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250905

**EFFECTIVENESS DATE**: 20250905

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Frazier Life Sciences Management, L.P.
- **CENTRAL INDEX KEY:** 0001892134

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-22504
- **FILM NUMBER:** 251296574

**BUSINESS ADDRESS:**
- **STREET 1:** 1001 PAGE MILL ROAD
- **STREET 2:** BUILDING 4, SUITE 200B
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304
- **BUSINESS PHONE:** (650) 325-5156

**MAIL ADDRESS:**
- **STREET 1:** 1001 PAGE MILL ROAD
- **STREET 2:** BUILDING 4, SUITE 200B
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94304

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001892134

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Frazier Life Sciences Management, L.P.

**Address:** 1001 PAGE MILL ROAD, PALO ALTO, CA 94304

**Telephone number:** 5165216874

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-22504

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** —

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                    | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                                                                                                              | VOTE CATEGORY                |   SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Acadia Pharmaceuticals Inc.       | 004225108 | 05/29/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |         470338 |                0 | FOR         |                                   470338 | FOR                         |  |
| Agios Pharmaceuticals, Inc.       | 00847X104 | 6/18/2025      | To vote, on an advisory basis, to approve the compensation paid to our named executive officers.                                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |        1279754 |                0 | FOR         |                                  1279754 | FOR                         |  |
| Alkermes Plc                      | G01767105 | 5/21/2025      | To approve, in a non-binding, advisory vote, the compensation of the Company's named executive officers.                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |        1000647 |                0 | FOR         |                                  1000647 | FOR                         |  |
| Allogene Therapeutics, Inc.       | 19770106  | 6/18/2025      | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement accompanying this notice.                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |        3868750 |                0 | FOR         |                                  3868750 | FOR                         |  |
| Arcutis Biotherapeutics Inc       | 03969K108 | 6/12/2025      | To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |        9769511 |                0 | FOR         |                                  9769511 | FOR                         |  |
| Autolus Therapeutics plc          | 05280R100 | 6/26/2025      | To approve the Directors' remuneration report (excluding the Directors' remuneration policy set out on pages 39 to 52 of Directors' remuneration report), which is set out on pages 36 to 65 of the 2024 Annual Report and Accounts.                                          | SECTION 14A SAY-ON-PAY VOTES |        4623324 |                0 | FOR         |                                  4623324 | FOR                         |  |
| Autolus Therapeutics plc          | 05280R100 | 6/26/2025      | To approve the Directors' remuneration policy set out on pages 39 to 52 within the Directors' remuneration report contained in the 2024 Annual Report and Accounts, which will take effect immediately after the end of the AGM.                                              | SECTION 14A SAY-ON-PAY VOTES |        4623324 |                0 | FOR         |                                  4623324 | FOR                         |  |
| Avidity Biosciences, Inc.         | 05370A108 | 6/10/2025      | To consider and vote upon, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission.                                               | SECTION 14A SAY-ON-PAY VOTES |         625000 |                0 | FOR         |                                   625000 | FOR                         |  |
| BridgeBio Pharma, Inc.            | 10806X102 | 6/20/2025      | To approve, on an advisory basis, the compensation of our named executive officers (NEOs), as disclosed in the Proxy Statement.                                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |        3800457 |                0 | FOR         |                                  3800457 | FOR                         |  |
| Cogent Biosciences, Inc.          | 19240Q201 | 6/4/2025       | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |        1737601 |                0 | FOR         |                                  1737601 | FOR                         |  |
| Disc Medicine, Inc.               | 254604101 | 6/11/2025      | To approve, on a non-binding, advisory basis, the compensation paid to our named executive officers.                                                                                                                                                                          | SECTION 14A SAY-ON-PAY VOTES |        1754834 |                0 | FOR         |                                  1754834 | FOR                         |  |
| Disc Medicine, Inc.               | 254604101 | 6/11/2025      | To recommend, by a non-binding advisory vote, the frequency of future advisory votes on the compensation paid to our named executive officers.                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |        1754834 |                0 | ONE YEAR    |                                  1754834 | FOR                         |  |
| Immunocore Holdings plc           | 45258D105 | 5/15/2025      | To approve, on advisory basis, the compensation of our named executive officers, as disclosed in the attached proxy statement.                                                                                                                                                | SECTION 14A SAY-ON-PAY VOTES |         384782 |                0 | FOR         |                                   384782 | FOR                         |  |
| Krystal Biotech, Inc.             | 501147102 | 5/16/2025      | To consider and act upon a non-binding, advisory vote on the compensation of our named executive officers.                                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |         688460 |                0 | FOR         |                                   688460 | FOR                         |  |
| MacroGenics, Inc.                 | 268157500 | 5/21/2025      | To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the attached proxy statement.                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |        3175665 |                0 | FOR         |                                  3175665 | FOR                         |  |
| Mereo BioPharma Group plc         | 589492107 | 5/13/2025      | That the compensation of the Company's named executive officers be approved, on an advisory (non-binding) basis.                                                                                                                                                              | SECTION 14A SAY-ON-PAY VOTES |        9265664 |                0 | FOR         |                                  9265664 | FOR                         |  |
| Mereo BioPharma Group plc         | 589492107 | 5/13/2025      | That the frequency of future advisory votes on the compensation of the Company's named executive officers be approved, on an advisory (nonbinding) basis.                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |        9265664 |                0 | THREE YEARS |                                  9265664 | FOR                         |  |
| NewAmesterdam Pharma Company N.V. | N62509109 | 6/4/2025       | Non-binding, advisory vote to approve the 2024 compensation of named executive officers.                                                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |       16116418 |                0 | FOR         |                                 16116418 | FOR                         |  |
| NewAmesterdam Pharma Company N.V. | N62509109 | 6/4/2025       | Non-binding, advisory vote regarding frequency of future shareholders' advisory votes on the compensation of named executive officers.                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |       16116418 |                0 | ONE YEAR    |                                 16116418 | FOR                         |  |
| Palvella Therapeutics, Inc.       | 697947109 | 6/10/2025      | Approval, on an advisory basis, of the compensation of the Company's named executive officer                                                                                                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |         697400 |                0 | FOR         |                                   697400 | FOR                         |  |
| Phathom Pharmaceuticals, Inc.     | 71722W107 | 6/3/2025       | To approve the compensation of the named executive officers on a non-binding advisory basis ("say-on-pay").                                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |       12466489 |                0 | FOR         |                                 12466489 | FOR                         |  |
| Phathom Pharmaceuticals, Inc.     | 71722W107 | 6/3/2025       | To approve a proposal for the frequency of future non-binding advisory votes on the compensation of the named executive officers ("say-on-frequency").                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |       12466489 |                0 | ONE YEAR    |                                 12466489 | FOR                         |  |
| Revolution Medicines, Inc.        | 76155X100 | 6/26/2025      | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this notice pursuant to the compensation disclosure rules of the Securities and Exchange Commission ("Say-on-Pay"); | SECTION 14A SAY-ON-PAY VOTES |         997455 |                0 | FOR         |                                   997455 | FOR                         |  |
| Rhythm Pharmaceuticals, Inc.      | 76243J105 | 9/18/2024      | Approval, on an advisory (non-binding) basis, of the compensation of the named executive officers of the Company.                                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |        2416952 |                0 | FOR         |                                  2416952 | FOR                         |  |
| Savara Inc.                       | 805111101 | 6/5/2025       | To approve, on an advisory basis, the compensation of our named executives.                                                                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |       11462301 |                0 | FOR         |                                 11462301 | FOR                         |  |
| Savara Inc.                       | 805111101 | 6/5/2025       | To indicate, on an advisory basis, the preferred frequency of holding an advisory vote on the compensation of our named executives.                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |       11462301 |                0 | ONE YEAR    |                                 11462301 | FOR                         |  |
| Silence Therapeutics plc          | G8128Y157 | 6/26/2025      | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |         970130 |                0 | FOR         |                                   970130 | FOR                         |  |
| Silence Therapeutics plc          | G8128Y157 | 6/26/2025      | To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of our named executive officers.                                                                                                                                 | SECTION 14A SAY-ON-PAY VOTES |         970130 |                0 | ONE YEAR    |                                   970130 | FOR                         |  |
| Tarsus Pharmaceuticals, Inc.      | 87650L103 | 6/12/2025      | To hold an advisory vote to approve, on a non-binding basis, our named executive officer compensation.                                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |        1397527 |                0 | FOR         |                                  1397527 | FOR                         |  |
| Tarsus Pharmaceuticals, Inc.      | 87650L103 | 6/12/2025      | To hold an advisory vote to approve, on a non-binding basis, the frequency with which future stockholder votes on the compensation of our named executive officers will be conducted of one, two or three years.                                                              | SECTION 14A SAY-ON-PAY VOTES |        1397527 |                0 | ONE YEAR    |                                  1397527 | FOR                         |  |
| Trevi Therapeutics, Inc.          | 89532M101 | 6/11/2025      | Approval, on an advisory basis, of the compensation paid to our named executive officers.                                                                                                                                                                                     | SECTION 14A SAY-ON-PAY VOTES |       10259409 |                0 | FOR         |                                 10259409 | FOR                         |  |
| Trevi Therapeutics, Inc.          | 89532M101 | 6/11/2025      | Approval, on an advisory basis, of the frequency of future advisory votes to approve the compensation paid to our named executive officers.                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |       10259409 |                0 | ONE YEAR    |                                 10259409 | FOR                         |  |
| Ultragenyx Pharmaceutical Inc.    | 90400D108 | 5/15/2025      | Advisory (Non-Binding) Vote to Approve the Compensation of our Named Executive Officers                                                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |         830915 |                0 | FOR         |                                   830915 | FOR                         |  |
| Valneva SE                        | 92025Y103 | 6/25/2025      | Approval of the compensation policy applicable to Mr. Thomas Lingelbach, CEO, for the fiscal year 2025                                                                                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |        1458333 |                0 | FOR         |                                  1458333 | FOR                         |  |
| Valneva SE                        | 92025Y103 | 6/25/2025      | Approval of the compensation policy applicable to Mr. Franck Grimaud, Associate Managing Officer, for the fiscal year 2025                                                                                                                                                    | SECTION 14A SAY-ON-PAY VOTES |        1458333 |                0 | FOR         |                                  1458333 | FOR                         |  |
| Valneva SE                        | 92025Y103 | 6/25/2025      | Approval of the compensation policy applicable to Mr. Juan Carlos Jaramillo, Associate Managing Officer, for the fiscal year 2025                                                                                                                                             | SECTION 14A SAY-ON-PAY VOTES |        1458333 |                0 | FOR         |                                  1458333 | FOR                         |  |
| Valneva SE                        | 92025Y103 | 6/25/2025      | Approval of the compensation policy applicable to Mr. Peter Buhler, Associate Managing Officer, for the fiscal year 2025                                                                                                                                                      | SECTION 14A SAY-ON-PAY VOTES |        1458333 |                0 | FOR         |                                  1458333 | FOR                         |  |
| Valneva SE                        | 92025Y103 | 6/25/2025      | Approval of the compensation policy applicable to Ms. Dipal Patel, Associate Managing Officer, for the fiscal year 2025                                                                                                                                                       | SECTION 14A SAY-ON-PAY VOTES |        1458333 |                0 | FOR         |                                  1458333 | FOR                         |  |
| Valneva SE                        | 92025Y103 | 6/25/2025      | Approval of the fixed, variable and exceptional components making up the total compensation and benefits of any kind paid during, or granted in respect of the fiscal year ended December 31, 2024, to Mr. Thomas Lingelbach, CEO                                             | SECTION 14A SAY-ON-PAY VOTES |        1458333 |                0 | FOR         |                                  1458333 | FOR                         |  |
| Valneva SE                        | 92025Y103 | 6/25/2025      | Approval of the fixed, variable and exceptional components making up the total compensation and benefits of any kind paid during, or granted in respect of the fiscal year ended December 31, 2024, to Mr. Franck Grimaud, Associate Managing Officer                         | SECTION 14A SAY-ON-PAY VOTES |        1458333 |                0 | FOR         |                                  1458333 | FOR                         |  |
| Valneva SE                        | 92025Y103 | 6/25/2025      | Approval of the fixed, variable and exceptional components making up the total compensation and benefits of any kind paid during, or granted in respect of the fiscal year ended December 31, 2024, to Mr. Juan Carlos Jaramillo, Associate Managing Officer                  | SECTION 14A SAY-ON-PAY VOTES |        1458333 |                0 | FOR         |                                  1458333 | FOR                         |  |
| Valneva SE                        | 92025Y103 | 6/25/2025      | Approval of the fixed, variable and exceptional components making up the total compensation and benefits of any kind paid during, or granted in respect of the fiscal year ended December 31, 2024, to Mr. Peter Buhler, Associate Managing Officer                           | SECTION 14A SAY-ON-PAY VOTES |        1458333 |                0 | FOR         |                                  1458333 | FOR                         |  |
| Valneva SE                        | 92025Y103 | 6/25/2025      | Approval of the fixed, variable and exceptional components making up the total compensation and benefits of any kind paid during, or granted in respect of the fiscal year ended December 31, 2024, to Ms. Dipal Patel, Associate Managing Officer                            | SECTION 14A SAY-ON-PAY VOTES |        1458333 |                0 | FOR         |                                  1458333 | FOR                         |  |
| Vaxcyte, Inc.                     | 92243G108 | 6/12/2025      | To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.                                                                                                                                           | SECTION 14A SAY-ON-PAY VOTES |         474405 |                0 | FOR         |                                   474405 | FOR                         |  |
| Verona Pharma plc                 | 925050106 | 4/24/2025      | To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.                                                                                                                                                                   | SECTION 14A SAY-ON-PAY VOTES |        3457850 |                0 | FOR         |                                  3457850 | FOR                         |  |
| Zai Lab Limited                   | 98887Q104 | 6/18/2025      | An ordinary resolution to approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement.                                                                                                                               | SECTION 14A SAY-ON-PAY VOTES |        1308138 |                0 | FOR         |                                  1308138 | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** Frazier Life Sciences Management, L.P.

**By (Signature):** Steve R. Bailey

**By (Printed Signature):** Steve R. Bailey

**By (Title):** CFO and CCO

**Date:** 09/02/2025